Quote:
Originally Posted by 1andrew1
The FT said there were actually two errors in the memo:
b) An incorrect name was used for the drug itself. The memo of 3rd October refers to it as a polyclonal antibody therapy whilst Regeneron's antibody therapy is monoclonal. Not an expert on the differences here eg if a cocktail is used, does it become "poly"?
b) Manufacturer's name, using the name Regeron instead of Regeneron. (Regeron focuses on reverse-aging biotechnology, especially on manufacturing human polypeptide growth factors for cosmetic applications including hair care).
A potential typo or genuine confusion with the other company.
|
Polyclonal is a mixture of T3 antibody cloned genes. Monoclonal uses the same cloned T3 antibody gene.